BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37728466)

  • 1. Nuclear expression of Ku70/80 is associated with CHEK2 germline mutations in breast cancer.
    Jakub R; Filip M; Daniel B; Jolanta H; Tomasz H; Cezary C; Jan L; Wenancjusz D; Domagała P
    Pol J Pathol; 2023; 74(2):75-81. PubMed ID: 37728466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and analysis of CHEK2 germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Fan Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Breast Cancer Res Treat; 2018 May; 169(1):59-67. PubMed ID: 29356917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
    Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
    Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unique ER PR expression pattern in breast cancers with CHEK2 mutation: a hormone receptor and HER2 analysis based on germline cancer predisposition genes.
    Wei G; Teng M; Rosa M; Wang X
    Breast Cancer Res; 2022 Feb; 24(1):11. PubMed ID: 35135604
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.
    Wang N; Ding H; Liu C; Li X; Wei L; Yu J; Liu M; Ying M; Gao W; Jiang H; Wang Y
    Oncogene; 2015 Oct; 34(40):5198-205. PubMed ID: 25619829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
    Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline
    Thibodeau ML; Reisle C; Zhao E; Martin LA; Alwelaie Y; Mungall KL; Ch'ng C; Thomas R; Ng T; Yip S; J Lim H; Sun S; Young SS; Karsan A; Zhao Y; Mungall AJ; Moore RA; J Renouf D; Gelmon K; Ma YP; Hayes M; Laskin J; Marra MA; Schrader KA; Jones SJM
    Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28514723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
    Schwartz CJ; Khorsandi N; Blanco A; Mukhtar RA; Chen YY; Krings G
    Breast Cancer Res Treat; 2024 Feb; 204(1):171-179. PubMed ID: 38091153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Risk for Other Cancers in Addition to Breast Cancer for CHEK2*1100delC Heterozygotes Estimated From the Copenhagen General Population Study.
    Näslund-Koch C; Nordestgaard BG; Bojesen SE
    J Clin Oncol; 2016 Apr; 34(11):1208-16. PubMed ID: 26884562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
    Stubbins RJ; Korotev S; Godley LA
    Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.
    Kilpivaara O; Bartkova J; Eerola H; Syrjäkoski K; Vahteristo P; Lukas J; Blomqvist C; Holli K; Heikkilä P; Sauter G; Kallioniemi OP; Bartek J; Nevanlinna H
    Int J Cancer; 2005 Feb; 113(4):575-80. PubMed ID: 15472904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHEK2 Germ Line Mutations are Lacking among Familial and Sporadic Breast Cancer Patients in Rwanda.
    Habyarimana T; Attaleb M; Mugenzi P; Mazarati JB; Bakri Y; El Mzibri M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):375-379. PubMed ID: 29479983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
    Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
    PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constitutional CHEK2 mutations are infrequent in early-onset and familial breast/ovarian cancer patients from Pakistan.
    Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
    BMC Cancer; 2013 Jun; 13():312. PubMed ID: 23806170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.
    Ow GS; Ivshina AV; Fuentes G; Kuznetsov VA
    Cell Cycle; 2014; 13(14):2262-80. PubMed ID: 24879340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer.
    Domagala P; Wokolorczyk D; Cybulski C; Huzarski T; Lubinski J; Domagala W
    Breast Cancer Res Treat; 2012 Apr; 132(3):937-45. PubMed ID: 21701879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
    Nasedkina TV; Gromyko OE; Emel'ianova MA; Ignatova EO; Kazubskaia TP; Portnoĭ SM; Zasedatelev AS; Liubchenko LN
    Mol Biol (Mosk); 2014; 48(2):243-50. PubMed ID: 25850293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.